Bibliography: library/10665-331525

The reference for library/10665-331525 (who-iris) and any references extracted from it. library · All references.

Export these 153 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

153 shown

  1. World Health Organization (2020). WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment. World Health Organization.
    10665-331525 · catalogue · link · repository record · ISBN 9789240002906 · source: catalogue/records/10665-331525.dc.json · held: library/10665-331525
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Med. 2016;13(10):e1002152.
    · extracted · source: references/10665-331525.sec-018.1.json
  3. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655.
    · extracted · source: references/10665-331525.sec-018.2.json
  4. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35.
    · extracted · source: references/10665-331525.sec-018.3.json
  5. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol. 1974;99(2):131–8.
    · extracted · source: references/10665-331525.sec-018.4.json
  6. Behr MA, Edelstein PH, Ramakrishnan L. Revisiting the timetable of tuberculosis. BMJ. 2018;362:k2738.
    · extracted · source: references/10665-331525.sec-018.5.json
  7. Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol. 2011;40(4):964–70.
    · extracted · source: references/10665-331525.sec-018.6.json
  8. The End TB Strategy. World Health Organization [website] (http://www.who.int/tb/strategy/en/ accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.7.json
  9. WHO End TB Strategy. World Health Organization [website]; 2013 (https://www.who.int/tb/post2015_strategy/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.8.json
  10. Framework towards tuberculosis elimination in low-Incidence countries. Geneva: World Health Organization; 2014 (http://www.ncbi.nlm.nih.gov/books/NBK254256/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.9.json
  11. Global tuberculosis report 2019. Geneva: World Health Organization; 2019 (http://www.who.int/tb/publications/global_report/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.10.json
  12. Political declaration of the High-Level Meeting of the General Assembly on the Fight Against Tuberculosis. UN General Assembly 73rd session; 2018 (http://digitallibrary.un.org/record/1649568, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.11.json
  13. WHO consolidated guidelines on tuberculosis: Module 1: Tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331170/9789240001503-eng.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.12.json · held: library/10665-331170
  14. Monitoring the building blocks of health systems: a handbook of indicators and their measurement strategies. Geneva: World Health Organization; 2010 (https://www.who.int/healthinfo/systems/WHO_MBHSS_2010_full_web.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.13.json
  15. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269–78.
    · extracted · source: references/10665-331525.sec-018.14.json
  16. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, Vries G de, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928–52.
    · extracted · source: references/10665-331525.sec-018.15.json
  17. Ford N, Matteelli A, Shubber Z, Hermans S, Meintjes G, Grinsztejn B, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.
    · extracted · source: references/10665-331525.sec-018.16.json
  18. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
    · extracted · source: references/10665-331525.sec-018.17.json
  19. Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (http://whqlibdoc.who.int/publications/2011/9789241500708_eng.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.18.json
  20. Bruins WS, Leth F van. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis. 2017;49(3):161–9.
    · extracted · source: references/10665-331525.sec-018.19.json
  21. Cotton M, Schaaf HS, Lottering G, Weber HL, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–7.
    · extracted · source: references/10665-331525.sec-018.20.json
  22. Cranmer LM, Kanyugo M, Jonnalagadda SR, Lohman-Payne B, Sorensen B, Maleche Obimbo E, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants: Pediatr Infect Dis J. 2014;33(4):401–6.
    · extracted · source: references/10665-331525.sec-018.21.json
  23. Kali PBN, Gray GE, Violari A, Chaisson RE, McIntyre JA, Martinson NA. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 1999. 2006;42(3):379–81.
    · extracted · source: references/10665-331525.sec-018.22.json
  24. Sterling TR, Alwood K, Gachuhi R, Coggin W, Blazes D, Bishai WR, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS. 1999;13(14):1899–904.
    · extracted · source: references/10665-331525.sec-018.23.json
  25. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–7.
    · extracted · source: references/10665-331525.sec-018.24.json
  26. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–44.
    · extracted · source: references/10665-331525.sec-018.25.json
  27. Crampin AC, Mwaungulu JN, Mwaungulu FD, Mwafulirwa DT, Munthali K, Floyd S, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–26.
    · extracted · source: references/10665-331525.sec-018.26.json
  28. Narayanan S, Swaminathan S, Supply P, Shanmugam S, Narendran G, Hari L, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
    · extracted · source: references/10665-331525.sec-018.27.json
  29. Chaisson RE, Churchyard GJ. Recurrent tuberculosis – relapse, reinfection and HIV. J Infect Dis. 2010;201(5):653–5.
    · extracted · source: references/10665-331525.sec-018.28.json
  30. Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrent-tuberculosis-relapse-versus-reinfection-and-related-risk-factors, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.29.json
  31. Systematic screening for active tuberculosis: principles and recommendations. Geneva: World Health Organization; 2013 (https://www.who.int/tb/tbscreening/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.30.json
  32. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012 (https://www.who.int/tb/publications/2012/contact_investigation2012/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.31.json
  33. WHO Guidelines on tuberculosis infection prevention and control, 2019 update Geneva: World Health Organization; 2019 (https://www.who.int/tb/publications/2019/guidelines-tuberculosis-infection-prevention-2019/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.32.json
  34. WHO Policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012 (http://whqlibdoc.who.int/publications/2012/9789241503006_eng_Annexes.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.33.json
  35. Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2013;41(1):140–156.
    · extracted · source: references/10665-331525.sec-018.34.json
  36. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8(6):359–368.
    · extracted · source: references/10665-331525.sec-018.35.json
  37. Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, et al. Feasibility of identifying household contacts of rifampin-and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020; 70(3):425–35.
    · extracted · source: references/10665-331525.sec-018.36.json
  38. Lung T, Marks GB, Nhung NV, Anh NT, Hoa NLP, Anh LTN, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–84.
    · extracted · source: references/10665-331525.sec-018.37.json
  39. Sulis G, Combary A, Getahun H, Gnanou S, Giorgetti PF, Konseimb A, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Organ. 2018;(96):386–92.
    · extracted · source: references/10665-331525.sec-018.38.json
  40. Prevent TB: a mobile app to support programmatic management of LTBI. Geneva: World Health Organization; 2020 (https://www.who.int/tb/prevent-tb-digital-platform/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.39.json
  41. Latent TB infection: Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018 (http://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.40.json
  42. Chest radiography in tuberculosis detection – summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (https://www.who.int/tb/publications/chest-radiography/en/, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.41.json
  43. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, et al. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183(8):1103–11.
    · extracted · source: references/10665-331525.sec-018.42.json
  44. TB Elimination. Interferon-Gamma Release Assays (IGRAs) – Blood tests for TB infection. Atlanta: Centre for Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, accessed 15 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.43.json
  45. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;(1) (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000171.pub3/abstract, accessed 15 March 2020).
    · extracted · doi:10.1002/14651858.CD000171.pub3/abstract · source: references/10665-331525.sec-018.44.json
  46. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–55.
    · extracted · source: references/10665-331525.sec-018.45.json
  47. Hamada Y, Ford N, Schenkel K, Getahun H. Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review Int J Tuberc Lung Dis 2018;22(12):1422–28.
    · extracted · source: references/10665-331525.sec-018.46.json
  48. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013;7 (DOI: 10.1002/14651858.CD007545.pub2, accessed 16 March 2020).
    · extracted · doi:10.1002/14651858.CD007545.pub2 · source: references/10665-331525.sec-018.47.json
  49. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17(1):265.
    · extracted · source: references/10665-331525.sec-018.48.json
  50. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization; 2015 (https://apps.who.int/medicinedocs/documents/s21682en/s21682en.pdf, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.49.json
  51. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.50.json
  52. January 2020. Medicines catalogue. Geneva: Global Drug Facility; 2020 (http://www.stoptb.org/assets/documents/gdf/drugsupply/GDFMedicinesCatalog.pdf, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.51.json
  53. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.
    · extracted · source: references/10665-331525.sec-018.52.json
  54. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016;30(10):1607–15.
    · extracted · source: references/10665-331525.sec-018.53.json
  55. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of rifapentine plus isoniazid to prevent hiv-related tuberculosis. N Engl J Med. 2019;380(11):1001–11.
    · extracted · source: references/10665-331525.sec-018.54.json
  56. Landmark deal secures significant discount on price of medicine to prevent TB. Press realease 2019. Unitaid [website] (https://unitaid.org/news-blog/landmark-deal-secures-significant-discount-on-price-of-medicine-to-prevent-tb/#en, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.55.json
  57. Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection Revisiting and revising concepts. Tuberculosis. 2015;95(4):373–84.
    · extracted · source: references/10665-331525.sec-018.56.json
  58. Catalyzing pediatric tuberculosis innovations (CaP TB): Short-course treatment regimens to prevent TB: 3HP and 3RH. Technical Brief. IMPAACT4TB [website] 2019 (https://www.impaact4tb.org/catalyzing-pediatric-tuberculosis-innovations-cap-tb-short-course-treatment-regimens-to-prevent-tb-3hp-and-3rh/, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.57.json
  59. TPT implementation tools. IMPAACT4TB [website] 2019 (https://www.impaact4tb.org/3hp-documents/, accessed 16 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.58.json
  60. Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61(4):191–6.
    · extracted · source: references/10665-331525.sec-018.59.json
  61. Biehl JP, Nimitz HJ. Studies on the use of a high dose of isoniazid. I. Toxicity studies. Am Rev Tuberc. 1954;70(3):430–41.
    · extracted · source: references/10665-331525.sec-018.60.json
  62. Oestreicher R, Dressler SH, Middlebrook G. Peripheral neuritis in tuberculous patients treated with isoniazid. Am Rev Tuberc. 1954;70(3):504–8.
    · extracted · source: references/10665-331525.sec-018.61.json
  63. Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug Healthc Patient Saf. 2014;6:145–9.
    · extracted · source: references/10665-331525.sec-018.62.json
  64. Money GL. Isoniazid neuropathies in malnourished tuberculous patients. J Trop Med Hyg. 1959;62(8):198–202.
    · extracted · source: references/10665-331525.sec-018.63.json
  65. Toman K, Frieden TR. Toman’s tuberculosis: case detection, treatment and monitoring ; questions and answers. 2nd edition. Geneva: World Health Organization; 2004.
    · extracted · source: references/10665-331525.sec-018.64.json
  66. McCune R, Deuschle K, Mcdermott W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc Pulm Dis. 1957;76(6):1100–5.
    · extracted · source: references/10665-331525.sec-018.65.json
  67. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. N Engl J Med. 1983;309(8):445–8.
    · extracted · source: references/10665-331525.sec-018.66.json
  68. Ghavanini AA, Kimpinski K. Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess. J Clin Neuromuscul Dis. 2014;16(1):25–31.
    · extracted · source: references/10665-331525.sec-018.67.json
  69. Sotgiu G, Matteelli A, Getahun H, Girardi E, Schepisi MS, Centis R, et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45(4):1170–3.
    · extracted · source: references/10665-331525.sec-018.68.json
  70. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555–64.
    · extracted · source: references/10665-331525.sec-018.69.json
  71. Comstock GW, Ferebee SH. How much isoniazid is needed for prophylaxis? Am Rev Respir Dis. 1970;101(5):780–2.
    · extracted · source: references/10665-331525.sec-018.70.json
  72. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.
    · extracted · source: references/10665-331525.sec-018.71.json
  73. Sandul AL, Nwana N, Holcombe JM, Lobato MN, Marks S, Webb R, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis. 2017;65(7):1085–93.
    · extracted · source: references/10665-331525.sec-018.72.json
  74. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.
    · extracted · source: references/10665-331525.sec-018.73.json
  75. Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization; 2017 (http://apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.74.json
  76. Leveraging differentiated ART delivery models for stable clients to scale up TB preventive therapy. Differentiated Service Delivery [Supplement]. Geneva: International AIDS Society (https://www.differentiatedcare.org/Portals/0/adam/Content/3qTmUzah5kWCdeEogdiJ5A/File/IAS%20TPT%20supplement%208-Pager%20DIGITAL.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.75.json
  77. Differentiated models of delivering HIV care: Perspectives from people living with HIV and health care workers in 7 African countries. ICAP HIV learning network_the CQUIN project for differentaited service delivery [website] (https://cquin.icap.columbia.edu/resources/issue-brief-differentiated-models-of-delivering-hiv-care/, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.76.json
  78. Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A, et al. Postpartum tuberculosis incidence and mortality among HIV-Infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–9.
    · extracted · source: references/10665-331525.sec-018.77.json
  79. Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: The Tshepiso Study. Clin Infect Dis. 2018;66(6):921–9.
    · extracted · source: references/10665-331525.sec-018.78.json
  80. Isoniazid tablet, USP. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.79.json
  81. Rifadin® (rifampin capsules USP) and Rifadin® IV (rifampin for injection USP). Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.80.json
  82. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, et al. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019;381(14):1333–46.
    · extracted · source: references/10665-331525.sec-018.81.json
  83. Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 2015;60(3):1234–41.
    · extracted · source: references/10665-331525.sec-018.82.json
  84. Partosch F, Mielke H, Stahlmann R, Gundert-Remy U. Exposure of nursed infants to maternal treatment with ethambutol and rifampicin. Basic Clin Pharmacol Toxicol. 2018;123(2):213–20.
    · extracted · source: references/10665-331525.sec-018.83.json
  85. Mngqibisa R, Kendall MA, Dooley K, Wu X, Firnhaber C, McIlleron H, et al. Pharmacokinetics and pharmacodynamics of depot medroxyprogesterone acetate (DMPA) in African women receiving treatment for HIV and TB: Potential concern for standard dosing frequency. Clin Infect Dis 2019; ciz863. doi: 10.1093/cid/ciz863, accessed 18 March 2020).
    · extracted · doi:10.1093/cid/ciz863 · source: references/10665-331525.sec-018.84.json
  86. Sadaphal P, Astemborski J, Graham NMH, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33(10):1687–91.
    · extracted · source: references/10665-331525.sec-018.85.json
  87. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B: AIDS. 2007;21(10):1301–8.
    · extracted · source: references/10665-331525.sec-018.86.json
  88. McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, et al. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017;72(7):2028–34.
    · extracted · source: references/10665-331525.sec-018.87.json
  89. Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
    · extracted · source: references/10665-331525.sec-018.88.json
  90. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–7.
    · extracted · source: references/10665-331525.sec-018.89.json
  91. Ahmed A, Lutchman GA, Kwo PY. Drug–drug interactions in hepatitis C virus treatment: Do they really matter? Clin Liver Dis. 2017;10(5):111–5.
    · extracted · source: references/10665-331525.sec-018.90.json
  92. Kempker RR, Alghamdi WA, Al-Shaer MH, Burch G, Peloquin CA. A pharmacology perspective of simultaneous tuberculosis and hepatitis C treatment. Antimicrob Agents Chemother. 2019 Oct 7; AAC.01215–19. doi: 10.1128/AAC.01215–19, accessed 18 March 2020).
    · extracted · doi:10.1128/AAC.01215–19 · source: references/10665-331525.sec-018.91.json
  93. Friedland G. Infectious disease co-morbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010;55(Suppl1):S37–42.
    · extracted · source: references/10665-331525.sec-018.92.json
  94. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34.
    · extracted · source: references/10665-331525.sec-018.93.json
  95. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48(1):72–82.
    · extracted · source: references/10665-331525.sec-018.94.json
  96. Mike F. An activist’s guide to rifapentine for the treatment of TB infection. New York: Treatment Action Group; 2019 (https://www.treatmentactiongroup.org/publication/an-activists-guide-to-rifapentine-for-the-treatment-of-tb-infection/, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.95.json
  97. Aquinas SM, Allan WGL, Horsfall PAL, Jenkins PK, Hung-Yan W, Girling D, et al. Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J. 1972;1(5803):765–71.
    · extracted · source: references/10665-331525.sec-018.96.json
  98. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–6.
    · extracted · source: references/10665-331525.sec-018.97.json
  99. Weiner M, Savic RM, Kenzie WRM, Wing D, Peloquin CA, Engle M, et al. Rifapentine Pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc. 2014;3(2):132–45.
    · extracted · source: references/10665-331525.sec-018.98.json
  100. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015;61(4):527–35.
    · extracted · source: references/10665-331525.sec-018.99.json
  101. Priftin (rifapentine) tablets. Highlights of prescribing information. Maryland: U.S. Food and Drug Administration; 2016 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.100.json
  102. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014;161(6):419–28.
    · extracted · source: references/10665-331525.sec-018.101.json
  103. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–66.
    · extracted · source: references/10665-331525.sec-018.102.json
  104. Pellagra and its prevention and control in major emergencies. Geneva: World Health Organization; 2000 (https://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.103.json
  105. Nursing guide for managing side effects to drug-resistant TB treatment. Berkeley: Curry international tuberculosis centre; 2018 (https://www.currytbcenter.ucsf.edu/products/view/nursing-guide-managing-side-effects-drug-resistant-tb-treatment, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.104.json
  106. William JB, Keith G, Charles P. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327–41.
    · extracted · source: references/10665-331525.sec-018.105.json
  107. HIV drug interaction checker. University of Liverpool [website] (https://www.hiv-druginteractions.org/checker, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.106.json
  108. Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD). HIV/AIDS. World Health Organization [website]; 2018 (http://www.who.int/hiv/topics/treatment/dtg-tld-briefing-web/en/, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.107.json
  109. Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020; 70(4):549–56.
    · extracted · source: references/10665-331525.sec-018.108.json
  110. Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, et al. Efavirenz pharmacokinetics and pharmacodynamics in hiv-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7.
    · extracted · source: references/10665-331525.sec-018.109.json
  111. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85.
    · extracted · source: references/10665-331525.sec-018.110.json
  112. van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111–8.
    · extracted · source: references/10665-331525.sec-018.111.json
  113. Dooley KE, Churchyard G, Savic RM, Gupta A, Marzinke M, Zhang N, et al. Safety & PK of weekly rifapentine/isoniazid (3HP) in adults with HIV on dolutegravir. Abstract 80. TB: From contact to cure and beyond. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sessions/safety-pk-weekly-rifapentineisoniazid-3hp-adults-hiv-dolutegravir, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.112.json
  114. López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002;41(9):681–90.
    · extracted · source: references/10665-331525.sec-018.113.json
  115. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, et al. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013;57(4):586–93.
    · extracted · source: references/10665-331525.sec-018.114.json
  116. Faren C, Dourumian S, Cantalloube C, Perrin L, Esposito V, Cierien-Puiseux I, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs. Abstract 493. Clinical Pharmacology of TB and HCV Coinfection. Conference on Retroviruses and Opportunistic Infections. March 4–7, 2019. Seattle, Washington (http://www.croiconference.org/sites/default/files/abstracts/493.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.115.json
  117. Medication Guide. Descovy® (emtricitabine and tenofovir alafenamide tablets). Foster City: Gilead Sciences (https://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_patient_pi.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.116.json
  118. Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother. 2019;74(6):1670–8.
    · extracted · source: references/10665-331525.sec-018.117.json
  119. Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé J-B, et al. Effect of isoniazid preventive therapy Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9.
    · extracted · source: references/10665-331525.sec-018.118.json
  120. Golub JE, Cohn S, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, et al. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. Clin Infect Dis. 2015;60(4):639–45.
    · extracted · source: references/10665-331525.sec-018.119.json
  121. Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med. 2014;370(4):301–10.
    · extracted · source: references/10665-331525.sec-018.120.json
  122. Kyaw NTT, Kumar AM, Kyaw KWY, Satyanarayana S, Magee MJ, Min AC, et al. IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality. Int Union Tuberc Lung Dis. 2019;23(3):322–30.
    · extracted · source: references/10665-331525.sec-018.121.json
  123. Wisaksana R, Hartantri Y, Lestari M, Azzahra D, Karjadi T, Yunihastuti E, et al. Benefit of isoniazid preventive therapy to reduce incident TB, mortality and loss to follow-up in Indonesian five-years cohort. 22nd International AIDS Conference (AIDS 2018); Amsterdam, Netherlands | 23–27 July 2018 (http://programme.aids2018.org/Abstract/Abstract/8205, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.122.json
  124. Comstock GW. Isoniazid prophylaxis in an undeveloped area. Am Rev Respir Dis. 1962;86:810–22.
    · extracted · source: references/10665-331525.sec-018.123.json
  125. Shanaube K, Sismanidis C, Ayles H, Beyers N, Schaap A, Lawrence K-A, et al. Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS ONE. 2009;4(11):e7749.
    · extracted · source: references/10665-331525.sec-018.124.json
  126. Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827–30.
    · extracted · source: references/10665-331525.sec-018.125.json
  127. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int Union Tuberc Lung Dis. 1999;3(10):847–50.
    · extracted · source: references/10665-331525.sec-018.126.json
  128. Smieja M, Marchetti C, Cook D, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 1999 (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001363/full, accessed 18 March 2020).
    · extracted · doi:10.1002/14651858.CD001363/full · source: references/10665-331525.sec-018.127.json
  129. Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine WL, Charalambous S, Martinson NA, Yimer G. Effectiveness of 3HP annually vs. once for HIV-positive people: the WHIP3TB trial. In: TUBERCULOSIS, OPPORTUNISTIC INFECTIONS, AND HIV TESTING. Boston, Massachusetts, USA; 2020. (https://www.croiconference.org/sessions/effectiveness-3hp-annually-vs-once-hiv-positive-people-whip3tb-trial, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.128.json
  130. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744–51.
    · extracted · source: references/10665-331525.sec-018.129.json
  131. den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(8): 1065–1071.
    · extracted · source: references/10665-331525.sec-018.130.json
  132. van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24(7):1051.
    · extracted · source: references/10665-331525.sec-018.131.json
  133. Best practice for the care of patients with tuberculosis. A guide for low-income countries. 2nd edition. Paris: International Union Against Tuberculosis and Lung Disease; 2017. (https://www.theunion.org/what-we-do/publications/technical/english/best-practice-2017-ENG.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.132.json
  134. Lutge EE, Wiysonge CS, Knight SE, Sinclair D, Volmink J. Incentives and enablers to improve adherence in tuberculosis. Cochrane Database Syst Rev. 2015;(9):CD007952. doi: 10.1002/14651858.CD007952.pub3.
    · extracted · doi:10.1002/14651858.CD007952.pub3 · source: references/10665-331525.sec-018.133.json
  135. Palacio A, Garay D, Langer B, Taylor J, Wood BA, Tamariz L. Motivational Interviewing improves medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2016;31(8):929–40.
    · extracted · source: references/10665-331525.sec-018.134.json
  136. Ethics guidance for the implementation of the End TB Strategy. Geneva: World Health Organization; 2017 (http://www.who.int/tb/publications/2017/ethics-guidance/en/, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.135.json
  137. Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology. 2010;15(4):603–22.
    · extracted · source: references/10665-331525.sec-018.136.json
  138. Chaisson RE, Golub JE. Preventing tuberculosis in people with HIV – no more excuses. Lancet Glob Health. 2017;5(11):e1048–9.
    · extracted · source: references/10665-331525.sec-018.137.json
  139. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. Morb Mortal Wkly Rep. 2018;67(25):723–6.
    · extracted · source: references/10665-331525.sec-018.138.json
  140. TB elimination. Tuberculin skin testing. Atlanta: Centre for Disease Control and Prevention; 2011 (https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.pdf, accessed 18 March 2020).
    · extracted · link · source: references/10665-331525.sec-018.139.json
  141. Morán-Mendoza O, Tello-Zavala MC, Rivera-Camarillo M, Ríos-Meza Y. Comparison of different methods and times for reading the tuberculin skin test. Int J Tuberc Lung Dis. 2013;17(10):1273–8.
    · extracted · source: references/10665-331525.sec-018.140.json
  142. Zahrani KA, Jahdali HA, Menzies D. Does size matter? Utility of size of tuberculin reactions for the diagnosis of mycobacterial disease. Am J Respir Crit Care Med. 2000;162(4):1419–22.
    · extracted · source: references/10665-331525.sec-018.141.json
  143. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111–5.
    · extracted · source: references/10665-331525.sec-018.142.json
  144. Chaturvedi N, Cockcroft A. Tuberculosis screening in health service employees: who needs chest X-rays? Occup Med. 1992;42(4):179–82.
    · extracted · source: references/10665-331525.sec-018.143.json
  145. Starke JR. Tuberculosis skin testing: new schools of thought. Pediatrics. 1996;98(1):123–5.
    · extracted · source: references/10665-331525.sec-018.144.json
  146. Nayak S, Acharjya B. Mantoux test and its interpretation. Indian Dermatol Online J. 2012;3(1):2–6.
    · extracted · source: references/10665-331525.sec-018.145.json
  147. Targeted tuberculin testing and treatment of latent tuberculosis infection. Morb Mortal Wkly Rep. 2000;49(RR06):1–54.
    · extracted · source: references/10665-331525.sec-018.146.json
  148. Sutherland I. The evolution of clinical tuberculosis in adolescents. Tubercle. 1966;47(3):308.
    · extracted · source: references/10665-331525.sec-018.147.json
  149. Veening GJ. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc. 1968;41:169–71.
    · extracted · source: references/10665-331525.sec-018.148.json
  150. Rothel JS, Jones SL, Corner LA, Cox JC, Wood PR. A sandwich enzyme immunoassay for bovine interferon-g and its use for the detection of tuberculosis in cattle. Aust Vet J. 1990;67(4):134–7.
    · extracted · source: references/10665-331525.sec-018.149.json
  151. Converse PJ, Jones SL, Astemborski J, Vlahov D, Graham NMH. Comparison of a tuberculin interferon-g assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis. 1997;176(1):144–50.
    · extracted · source: references/10665-331525.sec-018.150.json
  152. Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis. 1998;2(6):443–50.
    · extracted · source: references/10665-331525.sec-018.151.json
  153. Kay AW, Islam SM, Wendorf K, Westenhouse J, Barry PM. Interferon-g release assay performance for tuberculosis in childhood. Pediatrics. 2018;141(6):e20173918. Most people with TB infection are not sick and cannot spread the infection to others. However, they are at risk of developing active TB if their immune system weakens. What is TB infection? Tuberculosis (TB) is caused by bacteria that spreads through air and can infect anyone.
    · extracted · source: references/10665-331525.sec-018.152.json